Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29013903 | 0.92 | NOTUM (0.50) | NOTUMELANEMAPTCA1CA2 | |
| SCHEMBL5722940 | 0.85 | MAPT (0.59) | NOTUMELANEMAPTCA1CA2 | |
| SCHEMBL25852931 | 0.84 | NOTUM (0.57) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL2240748 | 0.82 | NOTUM (0.59) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL426745 | 0.79 | MAPT (0.62) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL30533381 | 0.79 | NOTUM (0.46) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL14139184 | 0.78 | ELANE (0.62) | NOTUMELANEMAPTCA1CA2 | |
| SCHEMBL21955097 | 0.78 | MDH1 (0.46) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL4159036 | 0.77 | HSD17B10 (0.47) | ELANEMAPTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL2193058 | 0.77 | SMN1; SMN2 (0.48) | ELANEMAPTKMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-112969504-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3873897-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3873605-A1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-112996786-A | Compounds for inhibiting alpha 4 beta 7 integrins | 吉利德科学公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-112969504-A | Compounds for inhibiting alpha 4 beta 7 integrins | 吉利德科学公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | NOTUM 4037/4885ELANE 571/4885MAPT 3224/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | NOTUM 4038/4885ELANE 624/4885MAPT 3196/4885 |
| US-20220226337-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | NOTUM 4037/4885ELANE 571/4885MAPT 3224/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | NOTUM 4037/4885ELANE 571/4885MAPT 3224/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | NOTUM 4037/4885ELANE 571/4885MAPT 3224/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | NOTUM 4037/4885ELANE 571/4885MAPT 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.